top of page

GHK-Cu Peptide Injection

Age Management of West Michigan

Integrative Medicine

Conventional, Functional, and Anti-Aging Regenerative Medicine located in Grand Rapids, MI.
Dr. Shahnaz Ali            Dr. Piyush Bhatnagar

background-blur-pale.jpg

AOD9604 (Anti-Obesity Drug) Benefits

Increases overall  Fat Burning

Increased Metabolism

Prevents formation of new fat cells

Reduces Body Fat in Abdomen region

Promotes ability to increase lean muscle mass

Prevents the loss of lean muscle during weight loss

Decreases body fat 30% faster than dieting alone

Joint and cartilage repair

Improves body's healing response

AOD9604 Side Effects

There are no known health risks associated with AOD 9604.The U.S. Food & Drug Administration recently assigned Human GRAS status to AOD 9604, meaning it is listed under the Generally Recognized As Safe (GRAS) program. This is a designation that identifies any food additive as safe when used as intended, per the Federal Food, Drug, and Cosmetic Act.

AOD9604 Contraindications:  AOD 9604 is not recommended for individuals who are pregnant or breast feeding.

AOD9604 Administration

AOD9604 is an oral capsule that is administered twice daily on an empty stomach.   AOD9604 is offered in a 4, 8, or 12 week cycle and can be used in conjunction with other peptides and hormone therapies.   A 4 week break is recommended after completion of 12 week cycle.

AOD9604  Combo Therapies

Weight Loss Combo

  • HCG (4 to 8 week cycle) / BPC157 / MOTS-C / Tesofensine / 5 Amino-1Q / (4 to 12 week cycle)

Regenerative Combo (Muscle/ Joints / Cartilage repair)​

  • BPC 157 / Follistatin 344 / KPV / MOTS-C / TB500  (4 to 12 week cycle)

Hormone Replacement Therapy

  • AOD9604 can be used in conjunction with BHRT, TRT, Sermorelin HGH Peptide, and other Peptide Therapies

doctor-patient-talking.jpg
Schedule your FREE consultation!

616.808.2695

Research and References

1.  Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8. doi: 10.1159/000053183. PMID: 11146367.

2.  STIER, H., VOS, E., KENLEY, D.. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism, North America, 3, apr. 2013.

3.  Mark Heffernan, Roger J. Summers, Anne Thorburn, Esra Ogru, Robert Gianello, Woei-Jia Jiang, Frank M. Ng, The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice andβ 3-AR Knock-Out Mice, Endocrinology, Volume 142, Issue 12, 1 December 2001, Pages 5182–5189, https://doi.org/10.1210/endo.142.12.8522

4.   “Obesity drug codenamed AOD9604 highly successful in trials,” News-Medical.net, 16-Dec-2004. [Online]. Available: https://www.news-medical.net/news/2004/12/16/6878.aspx. [Accessed: 24-May-2019].

5.   M. D. Jensen, “Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors,” Obes. Silver Spring Md, vol. 14 Suppl 3, pp. 143S-149S, Jun. 2006. 

6.   Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans      H Stier, E Vos, D Kenley - Journal of Endocrinology and Metabolism, 2013

​

bottom of page